Home Newsfeeds DA Davidson Maintains Neutral on Nu Skin Enterprises, Lowers Price Target to $34

DA Davidson Maintains Neutral on Nu Skin Enterprises, Lowers Price Target to $34

DA Davidson analyst Linda Bolton Weiser maintains Nu Skin Enterprises (NYSE:NUS) with a Neutral and lowers the price target from $40 to $34.

byBenzinga Newsdesk

November 23, 2022

1 minute read

DA Davidson analyst Linda Bolton Weiser maintains Nu Skin Enterprises (NYSE:NUS) with a Neutral and lowers the price target from $40 to $34.

Analyst Ratings

Breaking Down Neurocrine Biosciences: 8 Analysts Share Their Views

By Benzinga Insights

February 8, 10:00 AM

Ratings for Neurocrine Biosciences (NASDAQ:NBIX) were provided by 8 analysts in the past three months, showcasing a mix…

NBIX

Trinity Industries Announces $1.8B Multi-Year Railcar Order

By Benzinga Newsdesk

October 3, 8:42 AM

Trinity Industries, Inc. (NYSE:TRN) ("Trinity") announced that its subsidiary, Trinity Rail Group, LLC, has entered into a new long-term railcar supply agreement with GATX Corporation ("GATX") to

GATX

‘We Are Heading Into A New Bear Phase:’ Economist David Rosenberg Sounds Dire Warning On Key Signal In ‘Every Major Average’

By Shanthi Rexaline

August 18, 5:02 AM

He noted that every major average has broken below its 50-day moving average, including the Value-line Arithmetic and the S&P 500 Equal-Weight.

SPY

HC Wainwright & Co. Reiterates Buy on Replimune Group, Raises Price Target to $50

By Benzinga Newsdesk

February 10, 1:09 PM

HC Wainwright & Co. analyst Robert Burns reiterates Replimune Group (NASDAQ:REPL) with a Buy and raises the price target from $48 to $50.

REPL

DA Davidson Maintains Neutral on Nu Skin Enterprises, Lowers Price Target to $34

Related Posts

Breaking Down Neurocrine Biosciences: 8 Analysts Share Their Views

Trinity Industries Announces $1.8B Multi-Year Railcar Order

‘We Are Heading Into A New Bear Phase:’ Economist David Rosenberg Sounds Dire Warning On Key Signal In ‘Every Major Average’

HC Wainwright & Co. Reiterates Buy on Replimune Group, Raises Price Target to $50